Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (January 2025)
20 slides from Defence Therapeutics Inc Class A's investor presentation, January 2025
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q1 2025
Slide 2: Forward Looking Statements
Investor Presentation | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, includi
Slide 3: The Highlights
Investor Presentation | Defence Therapeutics THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Canada, with an attractive capital structure and long-term investors. ● Worldwide extensive patent portfolio of seven patent families related to four central functions o
Slide 4: Our Mandate
Our Mandate ● Complete licensing agreements with Antibody Drug Conjugates (ADCs) biotech and pharma companies to improve their ADCs efficacy and reduce their dosing for the benefit of the cancer patients ● Advance and bring to the clinic our most promising radiopharmaceuticals projects ● Focus on ou
Slide 5: Technology: Turning ADC challenges into proven platform solutions
Investor Presentation | Defence Theurapeutics Technology Turning ADC challenges into proven platform solutions Significance of Accum®Technology ACCUM® Talk-Worthy Results ACCUM® Innovative Approach CURRENT POOR Accum® EFFICIENT ACCUMULATION ACCUMULATION Overcoming problematic cell recycling Antibody
Slide 6: Defence Therapeutics: Innovative Platform
Investor Presentation | Defence Theurapeutics Defence Therapeutics: Innovative Platform Accum® Molecule BILE ACID NLS Highly Versatile Technology Ideal for the development of Easily applicable to mRNA-DNA- Molecules with anti- Augments the anti-tumoral novel cell-based vaccines or protein-based vacc
Slide 7: Valuable Project Traction
Investor Presentation | Defence Theurapeutics Valuable Project Traction With a highly flexible Accum® platform and 100% IP ownership, we have an impactful group of immuno- oncology and infectious disease treatments in development. Accum® is well- positioned to achieve data- driven value-inflection p
Slide 8: The AccuTOX Program
8 CANCER THERAPEUTICS The AccuTOX Program: Ready for Phase I in Canada, FDA clearance Study May Proceed in the USA Indication: Melanoma 8
Slide 9: AccuTOX-001 Halts Tumor Development with Checkpoint Inhibitors
Investor Presentation | Defence Theurapeutics AccuTOX-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors Synergistic effect against ICI- resistant Tumors 9
Slide 10: Defence Arm-X Cancer Vaccine
10 CANCER VACCINES Defence Arm-X Cancer Vaccine The solution to cure any solid cancer tumors 10
Slide 11: The AccuTOX-Reprogrammed MSC (ARM-X) Cancer Vaccine
Investor Presentation | Defence Theurapeutics The AccuTOX®-Reprogrammed MSC (ARM-X) Cancer Vaccine Patient admission and tumor resection Cell Processing Center Patient Treatment AccuTOX®/ANTIGEN REPROGRAMMING Immune-suppressive MSCs ARM-X 11 Time required to generate the ARM-X vaccine: 24 h
Slide 12: Pancreatic Cancer and B16 Melanoma Data
Investor Presentation | Defence Theurapeutics Pancreatic Cancer B16 Melanoma Ctl ARM-X PD-1 ARM-X + PD-1 1600 1000 PBS Tumor volume (mm3) Tumor Volume (mm3) Ctl PD-1 800 PD-1 1200 ARM-X ARM-X 600 ARM-X + PD-1 ARM-X + PD-1 800 MSC 400 400 MSC + PD-1 200 0 0 0 8 16 24 32 40 0 8 16 24 32 40 Timeline (D
Slide 13: The ADC Program
13 CANCER THERAPEUTICS The ADC Program: An example demonstrating how Accum can significantly improves any ADC 13
Slide 14: Defence improves ADCs efficacy
Investor Presentation | Defence Theurapeutics Defence improves ADCs efficacy We are not developing novel ADC, we are making any ADCs in development 20, 50 or even 100X better 1) The Accum® platform amplifies the therapeutics potency of any given ADC by ensuring its enhanced accumulation with lower d
Slide 15: XXX-ADC: The perfect example
Investor Presentation | Defence Theurapeutics XXX-ADC: The perfect example Accum® was conjugated onto an ADC developed by a European biotech that needed 60 mg/kg for in vivo potency. When Accum® was added, it showed in vivo therapeutic potency at 1mg/kg (60-fold enhancement) e e os os se st d n d d
Slide 16: The Radio-Immuno-Conjugates Programs
16 CANCER THERAPEUTICS The Radio-Immuno-Conjugates Programs: Indications: Solid Tumors 16
Slide 17: Radiopharmaceuticals Programs
Investor Presentation | Defence Theurapeutics Radiopharmaceuticals Programs 1) Accum®/AccuTOX® - Actinium 225 • 100% owned by Defence • Collaboration planned with the Canadian Nuclear Laboratories to perform the studies • Development of targeted radiopharmaceuticals therapy using Accum® & AccuTOX® w
Slide 18: Corporate: Management and Board of Directors
18 Corporate: Management and Board of Directors 18
Slide 19: Board Members, Advisors and Management
Investor Presentation | Defence Theurapeutics Board Members, Advisors and Management Sebastien Plouffe Dr. Philippe Lefrançois CEO, President, Founder & Director Director Financial expert and entrepreneur with 30+ years Director of Research in the derm atology experience with publicly listed compani
Slide 20: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Defence Therapeutics — Investor Presentation (January 2025) on 6ix